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ABSTRACT
We previously demonstrated elevated brain iron levels in myelinated structures and associated cells
in a hemochromatosis Hfe¡/¡xTfr2mut mouse model. This was accompanied by altered expression of
a group of myelin-related genes, including a suite of genes causatively linked to the rare disease
family ‘neurodegeneration with brain iron accumulation’ (NBIA). Expanded data mining and
ontological analyses have now identiﬁed additional myelin-related transcriptome changes in
response to brain iron loading. Concordance between the mouse transcriptome changes and
human myelin-related gene expression networks in normal and NBIA basal ganglia testiﬁes to
potential clinical relevance. These analyses implicate, among others, genes linked to various rare
central hypomyelinating leukodystrophies and peripheral neuropathies including Pelizaeus-
Merzbacher-like disease and Charcot-Marie-Tooth disease as well as genes linked to other rare
neurological diseases such as Niemann-Pick disease. The ﬁndings may help understand
interrelationships of iron and myelin in more common conditions such as hemochromatosis,
multiple sclerosis and various psychiatric disorders.
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Introduction
Neurodegeneration with Brain Iron Accumulation
(NBIA) comprises a family of rare, often fatal diseases
that can present with progressive motor dysfunction
such as dystonia, dysarthria and spasticity, visual
impairment and behavioral or cognitive problems.1
While iron accumulation in the basal ganglia is a com-
mon feature, most of the genes causatively associated
with the 10 published NBIA subtypes do not have
clear links to iron homeostasis and not all symptom-
atic patients with NBIA mutations have obvious iron
abnormalities, creating uncertainty as to the nature of
the relationships between iron accumulation and the
clinical and neuropathological features of NBIA.
In the past there have been few appropriate research
models for studying the effects of elevated iron in the
brain. Animal models have usually entailed short-term
iron loading by injection or dietary iron supplementa-
tion, with limited relevance to humans, where pathol-
ogy due to iron accumulation can take several years to
manifest clinically, even in the more aggressive iron dis-
eases.2 Although recent years have seen the emergence
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of genetically modiﬁed mouse models for studying
brain iron homeostasis, most have not exhibited sub-
stantiated increases in brain iron loading.
A new Hfe¡/¡xTfr2mut mouse model of the com-
mon iron loading disease hemochromatosis has now
been introduced that has simultaneous disruption of
the hemochromatosis Hfe and transferrin receptor 2
Tfr2 genes, on an AKR background, and hepatopatho-
logical signs of clinical hemochromatosis.3 We have
recently reported signiﬁcantly increased brain iron
loading in these mice relative to wildtype mice, the
ﬁrst such demonstration in a hemochromatosis
model, accompanied by subtle behavioral changes,
speciﬁcally hyperactivity and possibly also increased
aggression.4 Hemochromatosis in individuals with
combined mutations in both the TFR2 and HFE genes
is typically of earlier onset but otherwise clinically
indistinguishable from hemochromatosis caused by
either of these mutations alone.4
Compared to wildtype mice, Hfe¡/¡xTfr2mut mice
showed higher iron accumulation in myelinated struc-
tures throughout the brain, and in oligodendroglial cells
and other as yet unidentiﬁed cells, with few if any neu-
rons, astrocytes or microglia showing detectable iron
staining. Transcriptomic studies suggested that subtle
effects on molecular systems related to myelin might be
among the earliest pathological sequelae of increased
brain iron loading, rather than the neurodegenerative
changes iron is usually assumed to cause, such as direct
oxidative damage to neurons. This raises the possibility
that myelin pathology may provide a “missing link”
between abnormal brain iron accumulation and early
functional and behavioral sequelae.4
There were altered levels of the iron storage protein,
ferritin, linked to the NBIA subtype neuroferritinopathy,
and of transcripts for 5 other NBIA-associated genes
(ceruloplasmin Cp (MIM117700); phospholipase A2,
group VI Pla2g6 (MIM603604); fatty acid 2-hydroxylase
Fa2h (MIM611026); chromosome 19 open reading frame
12 C19orf12 (MIM614297) and ATPase type 13A2
Atp13a2 (MIM610513)). Myelin pathology has been
reported in NBIA patients or mice with mutations in
each of these genes, including the gene encoding ferritin,
and we also identiﬁed 16 other myelin-related genes with
decreased expression inHfe¡/¡xTfr2mut brain.4
As discussed in our earlier paper,4 no pathological
changes were observed in the gross structure or ultra-
structure of myelin. This is as expected, since the
Hfe¡/¡xTfr2mut mice can be considered equivalent to
the initial phases of human hemochromatosis, which
do not entail clinically signiﬁcant brain problems,
whereas in NBIA severe CNS phenotypes can be pres-
ent even very early in childhood. Nonetheless it
appears likely, in view of the substantial changes in
myelin gene expression observed in these mice, that
myelin-related molecular systems are affected to some
degree. This may potentially increase the likelihood of
myelin pathology developing in conjunction with other
causes, for example inappropriate immune responses.
As far as we know, this is the ﬁrst demonstration
that brain iron loading inﬂuences the expression of a
suite of genes causatively linked to NBIA, as well as
the ﬁrst demonstration of speciﬁc involvement of
myelin-related gene systems.4 Here we provide further
evidence for involvement of myelin-related systems in
mouse and human brain iron dyshomeostasis, with
expanded literature and array data mining revealing
17 new myelin-related genes showing altered expres-
sion in the mouse model and 74 new myelin-related
genes showing altered expression in the human NBIA
brain. Some of these genes are causally linked to rare
myelin diseases in which iron has not previously been
implicated. We also explore the possibility that pertur-
bation of normal relationships between iron and mye-
lin may be a shared feature both of several groups of
rare brain diseases and of various more common dis-
orders, including the iron overload disease hemochro-
matosis, the myelin disease multiple sclerosis and
psychiatric conditions such as major depressive disor-
der, bipolar disorder, autism and schizophrenia.
Methods
Animals, tissue collection and iron staining
Mice with homologous recombinant knockout of theHfe
gene and mice with the Y245X nonsense mutation in the
Tfr2 gene (both on AKR background) were cross-bred to
generate Hfe¡/¡xTfr2mut mice, as described previously.3
Male wildtype mice were maintained on a standard diet
containing »0.02% iron. To maximize iron status, male
Hfe¡/¡xTfr2mutmice were fed an iron-supplemented diet
containing 2% iron for 3 weeks before sacriﬁce at 3
months of age; as previously reported, dietary iron sup-
plementation by this regimen does not increase brain
iron levels in wildtype mice.5 Iron in brain sections was
detected by 3,30-diaminobenzidine (DAB)-enhanced
Perls’ stain.4 All protocols were approved by the Animal
e1198458-2 M. HEIDARI ET AL.
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Ethics Committees of the University of Western Aus-
tralia and the University of Sydney.
Gene expression measurement and analysis
Total RNA isolation, labeling, ampliﬁcation and
microarray probe hybridization were performed using
previously described methods6,7 on brain homoge-
nates from Hfe¡/¡xTfr2mut mice and wildtype mice
(n  4 ) and on post-mortem basal ganglia of 2 clini-
copathologically conﬁrmed NBIA cases of unknown
genetic subtype (male 66 years and female 81 years),
from the Canadian Brain Tissue Bank, University of
Toronto, and 2 age and gender-matched adults with
no diagnosed neurological conditions from the New-
castle Brain Tissue Resource, Newcastle University,
UK.4 Sentrix MouseRef-8 v2 Expression BeadChips or
HumanHT-12 v4 Expression BeadChips (Illumina)
were used to assess gene expression, with data pre-
processing, background subtraction, normalization
and differential expression analysis as detailed else-
where.4,8 Tissue was obtained with fully informed con-
sent and the study approved by the Human Research
Ethics Committee of the University of Newcastle, Aus-
tralia (H-2010-1219).
An expanded list of myelin-related genes was gen-
erated by more extensive literature searching and
application of an augmented suite of bioinformatics
tools including DAVID (http://david.abcc.ncifcrf.gov/
home.jsp), KEGG (http://www.genome.jp/kegg/),
NCBI Biosystems (http://www.ncbi.nlm.nih.gov/bio
systems/) and AmiGO2 (http://amigo.geneontology.
org/amigo). This list was compared to the differen-
tially expressed genes from the Hfe¡/¡xTfr2mut brain,
the NBIA patient brains and 2 modules of genes show-
ing expression correlations in normal human basal
ganglia and enriched for both NBIA-related genes and
genes related to myelin and oligodendrocytes, con-
structed from 101 normal human brains as described
previously.4,9
Results
As already reported, inductively coupled plasma
atomic emission spectroscopy (ICP-AES) showed that
whole brain homogenates from Hfe¡/¡xTfr2mut mice
at 3 months of age contained higher levels of iron
than gender- and age-matched wildtype controls.4
This was conﬁrmed by Perls’ staining, which also
revealed similar anatomical patterns of heterogeneous
iron distribution in Hfe¡/¡xTfr2mut mice fed a high
iron diet to those seen in wildtype mice on a standard
diet, with iron predominantly localized to myelinated
structures and myelin-associated cells and with partic-
ularly high levels in basal ganglia (Fig. 1).
We investigated an expanded list of putative mye-
lin-related genes (n = 172), as detailed in Methods.
This new list includes all but one of the published
NBIA genes. Genes that were not considered strongly
myelin-related in the previous paper but which have
now been included in the new list based on the exis-
tence of at least 2 independent reports of oligodendro-
cyte or myelin-related effects are Pank2,10,11 Cp,12,13
Dcaf1714,15 and Wdr45,16,17 although not all patients
with each of these mutations invariably have evidence
of myelin effects.4 Coasy has not been included but
this may change in the future as patient series with
post-mortem data are reported.
We also noted that a putative eleventh NBIA
gene, RALBP1 associated Eps domain containing 1
(REPS1), was reported in the conference proceed-
ings of the American Society of Human Genetics
meeting, Boston, US, 2013.18 Our expression analy-
sis found that transcript levels of this gene are
unchanged in either the Hfe¡/¡xTfr2mut mice
(p > 0.05) or in the 2 human NBIA basal ganglia
analyzed in our study. There so far appears to be no
evidence for relationships with myelin or iron but
little is yet known about this protein. We did not
include this gene in the full analysis as it is not yet a
conﬁrmed NBIA gene.
Of the expanded list of 172 genes, the array did not
contain speciﬁc probes for 35 genes and a further 30
genes failed to pass the detection threshold (p > 0.01)
in both Hfe¡/¡xTfr2mut and wildtype mice. Of the
remaining 107 genes, 40 genes (»37%) were differen-
tially expressed in the brain of Hfe¡/¡xTfr2mut mice
compared with wildtype mice (p0 .05). This suggests
the myelin transcriptome is speciﬁcally affected in
these mice, since this proportion is signiﬁcantly higher
(Chi square p<0.0001) than that for the full transcrip-
tome, with »21% of the total number of expressed
genes (n = 12,318) showing altered transcript levels in
the brain of the Hfe¡/¡xTfr2mut mice compared to
wildtype mice.
Of the 40 differentially expressed myelin-related
genes, 21 myelin-related genes were identiﬁed in our
earlier work (comprising 5 NBIA genes and 16 other
myelin-related genes), all having decreased transcript
RARE DISEASES e1198458-3
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levels in Hfe¡/¡xTfr2mut brain except ferritin, for
which transcripts were unchanged but protein levels
increased.4 Of the 19 newly identiﬁed genes, all but 3
also showed decreased expression (Table 1). The pro-
portion of myelin-related genes with decreased tran-
script levels in Hfe¡/¡xTfr2mut brain (90%) is
signiﬁcantly higher (Chi square p < 0.0015) than that
for the brain transcriptome overall (»66%). The list
includes genes encoding prominent myelin compo-
nents such as myelin-associated glycoprotein (Mag)
(MIM159460) and myelin oligodendrocyte glycopro-
tein (Mog) (MIM159465) as well as genes involved in
myelin biogenesis, regulation and other relevant func-
tions (For the full list of all 40 myelin-related genes
identiﬁed in the mouse model see Table 1; for referen-
ces for each gene see Table S1).
We investigated the concordance of the set of 40
myelin-related genes from our mouse model of brain
iron loading and a set of myelin-related genes co-
expressed with NBIA-related genes in normal human
brain. Two normal human basal ganglia gene co-
expression modules enriched for both NBIA-related
genes and genes related to myelin and oligodendro-
cytes were generated from analyses of 101 human
brains.4,9 In total these modules contained 17 (»42%)
of the 40 genes (ATP13A2, BACE1, C19orf12,
CLDN11, CNP, FA2H, H6PD, MAG, MOG, MTMR2,
PSAP, RTN4, SGPP2, SLC12A6, SMPD1, SOD1, TF).
Post-mortem NBIA brain samples are difﬁcult to
obtain but we have previously performed gene expres-
sion arrays on basal ganglia tissue from 2 clinicopath-
ologically conﬁrmed NBIA patients and matched
Figure 1. Iron labeling by DAB-enhanced Perls’ staining in wildtype and Hfe¡/¡xTfr2mut mouse brain at 3 months of age. Iron is mainly
accumulated in myelinated structures and associated cells. Myelin (M), oligodendrocyte (O), blood vessel (V) and black arrows show neu-
rons (N) which do not accumulate appreciable iron even in the Hfe¡/¡xTfr2mut mouse brain.
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Table 1. Myelin-related genes identiﬁed as differentially expressed in i. the Hfe¡/¡xTfr2mut mice in comparison with wildtype mice and
ii. NBIA post-mortem basal ganglia samples compared to neurologically healthy control samples. FC: fold change. Asterisks indicate
genes that were not reported as myelin-related genes in our previous paper.
Gene name and symbol Function of encoded protein
Hfe¡/¡xTfr2mut
FC (p value) NBIA case 1 NBIA case 2
NBIA-related genes
Ferritin, light polypeptide Ftl Iron storage "2.3 (0.0005) – –
Phospholipase A2, group VI Pla2g6 Fatty acid release from phospholipids #1.60 (0.010) – –
Fatty acid 2-hydroxylase Fa2h 2-hydroxy sphingolipid synthesis #1.41 (0.002) – –
Ceruloplasmin Cp Oxidation of Fe(II) to Fe(III), supports myelination in absence
of hephaestin
#1.35 (0.013) – –
Chromosome 19 open reading frame
12 C19orf12
Fatty acid biogenesis #1.28 (0.023) – –
ATPase type 13A2 Atp13a2 Ceramide synthesis in lysosomes, phospholipid distribution in
myelin
#1.17 S(0.047) – –
Myelin Structure and Biogenesis
Hexose-6-phosphate dehydrogenase
H6pd
Involved in NADPH production for myelin fatty acid synthesis,
strongly enriched in oligodendrocytes
#1.67 (0.0004) – –
Myelin-associated oligodendrocytic
basic protein Mobp
Major myelin component, compacting and stabilizing the
myelin sheath
#1.48 (0.0004) #2.60 #2.83
20 ,30-cyclic nucleotide 30
phosphodiesterase Cnp
Major myelin component, hydrolyzes 20 ,30-cyclic nucleotides
to 20 derivatives
#1.27 (0.0033) – –
Myelin oligodendrocyte glycoprotein
Mog
Myelin surface component #1.14 (0.0398) "1.80 "2.44
Myelin-associated glycoprotein Mag Myelin-axon interactions #1.13 (0.0301) "2.41 "2.44
Sphingosine-1-phosphate
phosphatase 2 Sgpp2
Catalyzes degradation of sphingosine-1-phosphate
regenerating sphingosine
#1.40 (0.0001) "1.91 "2.06
Neutral sphingomyelinase (N-SMase)
activation associated factor Nsmaf
Activation of neutral sphingomyelinase #1.34 (0.0142) "1.52 "2.36
Sphingomyelin phosphodiesterase
Smpd1
Converts sphingomyelin to ceramide #1.25 (0.0001) "2.40 –
Prosaposin Psap Sphingolipid activation #1.16 (0.0043) #1.82 "1.57
Cytochrome P450, family 51 Cyp51 Involved in cholesterol synthesis required for myelination #1.13 (0.0261) – –
Reticulon 4 RTN4 Myelin outgrowth inhibitor #1.33 (0.034) – –
Oligodendrocyte speciﬁc protein/
claudin 11 Cldn11
Myelin compaction #1.13 (0.0127) – –
Gap junction protein, gamma 2 Gjc2 Gap junction protein with roles in myelination, mutation
causes progressive leukodystrophy
#1.27 (0.0052) #2.47 #2.87
Tetraspanin 2 Tspan2 Involved in oligodendrocyte differentiation to generate
myelin, stabilizes myelin
#1.22 (0.0238) – –
Heat shock 60 kDa protein 1 Hspd1 Involved in myelin development, mutation causes
hypomyelinating leukodystrophy
#1.31 (0.0004) – #2.01
Annexin A2 Anxa2 Involved in paranodal regions in peripheral myelin, induces
membrane budding and lipid segregation
#1.11 (0.0184) "1.70 "1.60
Multiple PDZ domain protein Mpdz Involved in oligodendrocyte-astrocyte gap junctions and tight
junctions in myelinating Schwann cells
#1.16 (0.0229) – "1.62
Exocyst complex component 4 Exoc4 Regulates transport of myelin proteins to site of membrane
growth in oligodendrocytes and Schwann cells
#1.16 (0.0464) – –
Aldo-keto reductase family 1,
member B1 Akr1b1
Present in myelin, catalyzes NADPH-dependent reduction of
glucose to sorbitol, implicated in diabetic neuropathy
"1.20 (0.0111) – –
Other myelin-related functions
Klotho Kl Enhances oligodendrocyte maturation and myelination #1.38 (0.0003) – –
Transferrin Tf Iron transport and Mbp transcription regulator #1.33 (0.00002) – "1.98
Solute carrier family 12, member 6
Slc12a6
Myelin development, mutation causes agenesis of the corpus
callosum
#1.29 (0.0180) – –
Histamine receptor H3 Hrh3 Myelin component, involved in experimental autoimmune
encephalomyelitis (EAE) development
#1.25 (0.041) – –
Ring ﬁnger protein 10 Rnf10 Transcriptional regulation of the myelin-associated
glycoprotein gene
#1.21 (0.0448) "1.91 –
Tumor necrosis factor receptor
superfamily, member 21 Tnfrsf21
Negatively regulates oligodendrocyte survival, maturation and
myelination
#1.50 (0.0029) #4.25 #1.85
Leucine rich repeat and Ig domain
containing 1 Lingo1
Negatively regulates myelination #1.20 (0.0169) – –
Myotubularin related protein 2
Mtmr2
Negatively regulates membrane formation in Schwann cells,
linked to Charcot-Marie-Tooth disease type 4B1
#1.19 (0.0489) #1.58 –
Superoxide dismutase 1, soluble
Sod1
Oligodendrocyte maturation, linked to amyotrophic lateral
sclerosis
"1.12 (0.0366) #2.31 "1.52
Beta-site APP-cleaving enzyme 1
Bace1
Enhances myelination, cleaves the amyloid precursor protein
at the b-secretase site
#1.10 (0.0117) – –
Kallikrein-related peptidase 8 Klk8 Demyelination and oligodendrocyte death in experimental
allergic encephalomyelitis (EAE) is attenuated in Klk8
knockouts
"1.22 (0.0183) – –
(Continued on next page )
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controls.4 To examine whether myelin-related gene
transcript levels are selectively affected in human
NBIA patients, we compared this human NBIA data-
set with the full list of 172 myelin-related genes (com-
prising the 107 genes expressed in the mouse brain as
well as those myelin-related genes either not expressed
or not represented on the mouse array). Of these 172
genes, 136 were represented on the human array
(DCAF17 being one notable exception), of which 91
were expressed in the basal ganglia (Cp expression
was not detected). Of these, 74 (»81%) had putatively
altered transcript levels in one or more of the NBIA
cases compared to controls, with 49 (»54%) of these
having putatively altered transcript levels in both
NBIA patients, though not always in the same direc-
tion (for the full list of 74 genes see Table S2). This
suggests the myelin transcriptome may be speciﬁcally
affected in at least some NBIA patients, since the pro-
portion of myelin-related genes with altered expres-
sion in one or more of the NBIA cases (»81%) was
signiﬁcantly higher (Chi square p < 0.0001) than that
for the full transcriptome, with »55% of all genes
expressed in the basal ganglia and detected by the
array. Similarly the proportion of myelin-related genes
with altered expression in both NBIA cases (»54%)
was signiﬁcantly higher (Chi square p < 0.0004) than
that for the full transcriptome, with »36% of all genes
expressed in the basal ganglia and detected by the
array.
Myelin-related genes putatively affected in NBIA
basal ganglia include important structural components
of myelin e.g. MBP (MIM159430), PLP1
(MIM300401),MAG, MOG and MOBP (MIM600948),
as well as genes involved in myelin or oligodendrocyte
regulation such as MYT1 (MIM600379), LINGO1
(MIM609791), ASCL1 (MIM100790), RNF10
(MIM615998) and TNFRSF21 (MIM605732), encoding
death receptor 6. As detailed in Table 1, of the 40 mye-
lin-related genes with altered expression in the mouse
brain, 17 (»42%) are among the 74 myelin-related
genes with putatively altered expression in the NBIA
brains. Various other important myelin-related genes
with putative expression changes in NBIA humans but
not mouse are listed in Table 2.
Discussion
The new ﬁndings support our contention that supra-
normal iron accumulation in myelinated structures
and oligodendrocytes substantially modiﬁes the mye-
lin-related transcriptome, altering transcript levels for
a range of disease-associated genes and potentially
affecting numerous important myelin-related molecu-
lar systems. As noted elsewhere,4 we attribute this to
brain iron accumulation rather than other changes
Table 1. (Continued )
Gene name and symbol Function of encoded protein
Hfe¡/¡xTfr2mut
FC (p value) NBIA case 1 NBIA case 2
Ganglioside induced differentiation
associated protein 1 Gdap1
Mitochondrial ﬁssion factor, Gdap1-knockouts develop
hypomyelinating peripheral neuropathy
#1.12 (0.0380) – –
Fibroblast growth factor receptor 3
Fgfr3
Regulates oligodendrocyte terminal differentiation and timing
of myelination, regulates injury-related effects in the
peripheral nervous system
#1.27 (0.0382) – #6.24
Neurotrophic tyrosine kinase,
receptor, type 2 Trkb
Regulates CNS myelination and progenitor cell proliferation
through its ligand, brain derived neurotrophic factor
(BDNF)
#1.16 (0.0331) – –
SRY (sex determining region Y)-box
17 Sox17
Regulates oligodendrocyte progenitor cell cycle exit and
differentiation, oligodendrocyte survival
#1.74 (0.0426) – –
Table 2. Some important myelin-related genes identiﬁed as dif-
ferentially expressed in NBIA post-mortem basal ganglia samples
compared to neurologically healthy control samples (asterisks
indicate newly identiﬁed genes).
Gene name and symbol
NBIA
case 1
NBIA
case 2
NBIA-related genes
Pantothenate kinase 2 PANK2 #3.80 "1.56
WD repeat domain 4 WDR45 "1.99 "1.56
Myelin Structure and Biogenesis
Myelin basic protein MBP "2.33 "1.82
Mal T-cell differentiation protein MAL "1.94 "3.23
Oligodendrocyte myelin glycoprotein OMG "1.89 "2.35
Proteolipid protein 1 PLP1 – "4.1
Other myelin-related functions
Oligodendrocytic myelin paranodal and
inner loop protein OPALIN
"2.70 "3.30
Dicer 1 ribonuclease III DICER1 "2.53 "3.51 #1.68
B-cell CLL/lymphoma 2 BCL2 "2.52 –
Achaete-scute family bHLH transcription
factor 1 ASCL1
"2.30 –
Niemann-Pick disease, type C1 NPC1 "2.13 "4.08
Peripheral myelin protein 2 PMP2 – "1.61
Myelin transcription factor 1 MYT1 – #3.70
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caused by either of the 2 mutated genes, since these
responses were not observed in the single mutant
mouse models used to generate the Hfe¡/¡xTfr2mut
mice, neither of which show increased brain iron lev-
els despite elevated liver and blood iron.
The ﬁndings suggest a close, 2-way interrelation-
ship between iron and myelin. We hypothesize ﬁrst
that perturbation of myelin systems is among the ini-
tial consequences of brain iron dyshomeostasis, occur-
ring at the very earliest stages of pre-clinical disease,
and second that pathology may escalate in patients
unable to mount adequate compensatory responses,
with most myelin systems being affected by end-stage
disease. Conversely we hypothesize that mutations in
some myelin-related genes, notably various NBIA
genes, will directly or indirectly reduce the iron stor-
age capacity of myelin, resulting in abnormal iron
deposition or lability.
Notwithstanding this mutual interdependence,
excessive iron loading is likely to have different conse-
quences from mutations in myelin-related genes.
Mutation of any one myelin-related gene will not
inevitably affect the capacity of myelin to store iron,
even if the mutation causes clinical sequelae involving
other functions such as nerve conduction or axon pro-
tection. Even when a single mutation has the potential
to affect iron storage capacity, the phenotypic conse-
quences may differ between patients depending on
individual variations in any of a number of potential
exacerbating or compensating factors involving other
myelin or iron regulatory systems. This may explain
why brain iron accumulation is not always present in
patients with NBIA mutations.
In contrast, our results suggest that excessive
increases in iron within myelinated structures and asso-
ciated cells will eventually lead to widespread down-
stream consequences in numerous myelin systems,
including transcription changes of multiple myelin-
related genes. Our analyses are also revealing unexpected
connections with another set of rare diseases involving
myelin but not, as far as we know, previously recognized
to involve iron. Notably we observed decreased tran-
script levels in both Hfe¡/¡xTfr2mut mouse and at least
one human NBIA case for 2 genes encoding proteins
with different functions yet both causatively linked to
very rare hypomyelinating leukodystrophies, the heat
shock protein 60 HSPd1 gene, linked to mitochondrial
Hsp60 chaperonopathy (MIM612233), and the gap
junction GJC2 gene, linked to both Pelizaeus-
Merzbacher-like disease (MIM608804) and a mild, late-
onset, slowly progressive, complicated spastic paraplegia
(MIM613206). Decreased transcript levels may give rise
to partial loss-of-function phenotypes but further
research is needed to determine the effects, if any, in our
model.
Regarding spastic paraplegias and other peripheral
diseases, we focused on genes considered primarily
relevant to central nervous system (CNS) myelin but
also noted changes in transcript levels for various
genes important for peripheral myelin, including
peripheral myelin protein 2 Pmp2 (MIM170715),
annexin Anxa2 (MIM151740), Gdap1 (MIM606598)
and Mtmr2 (MIM603557), both linked to Charcot-
Marie-Tooth peripheral neuropathies. Systematic
investigation will probably reveal more such genes in
the future. Few if any investigations have applied
modern iron staining techniques in the peripheral ner-
vous system in such diseases or in the common iron
disorder hemochromatosis but a 2010 study reported
a high rate (26%) of idiopathic polyneuropathy in a
small clinical series of hemochromatosis patients
(n = 46).19
The large number of myelin-related genes with
altered transcript levels is perhaps more indicative of
generalized actions of iron on myelin per se rather
than speciﬁc effects of iron loading on the transcript
levels of individual genes. As transcript levels were
almost invariably decreased in the mouse model, one
possibility is that excess iron leads to myelin degrada-
tion, causing a gross decrease in total brain myelin
and proportionate decreases of myelin transcripts rel-
ative to total brain transcripts. However, as we
reported earlier, semi-quantitative analyses revealed
no apparent differences in myelination by electron
microscopy or in gross myelin content by Luxol fast
blue staining and there were no transcript level
changes for 2 major myelin structural components,
MBP and PLP.4 Instead there may be more subtle
adjustments in myelin structural and regulatory sub-
systems as the amount of iron stored in myelin starts
to ramp up beyond normal levels. For example, some
of the transcripts showing changes in Hfe¡/¡xTfr2mut
mouse or humans, such as Opalin (Gene ID 93377),
Mtmr2 and Anxa2, encode genes important in myelin
paranodal regions and may have subtle effects on the
nodes of Ranvier and nerve conduction properties or
on the axon without affecting myelin quantity or gross
integrity. In addition, altered expression of some
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neuronal genes may cause myelin problems. For
example, the SLC12A6 gene, which shows decreased
expression in the Hfe¡/¡xTfr2mut mouse brain, codes
for the neuronal potassium- and chloride-cotrans-
porter 3 (KCC3).20 Mutations in SLC12A6 are associ-
ated with hereditary motor and sensory neuropathy
with agenesis of corpus callosum (HMSN/ACC), with
axonal swelling and myelin impairment.21 Dysfunc-
tion of this transporter therefore appears to affect the
axonal ion-ﬂuid osmotic equilibrium, resulting in local
edema and potentially indirectly affecting myelin.
In this regard it is worth noting that various genes
identiﬁed in our analyses have roles beyond their mye-
lin-related functions. As just one example, the Klotho
(Kl) gene (MIM604824) is implicated in major myelin
pathways, with null mutant mice showing impaired
myelination, but has also been reported to confer
resistance to oxidative stress22 and to protect hippo-
campal and dopaminergic neurons from neurodegen-
eration by regulating redox systems,23,24 as well as
having roles in suppression of aging.25,26 The reduced
expression of Klotho in the Hfe¡/¡xTfr2mut mice
might therefore confer increased vulnerability to vari-
ous degenerative changes, whether involving myelin,
neurons or other brain systems.
The hemochromatosismodeled by theHfe¡/¡xTfr2mut
mouse would usually be considered likely to be far less
severe than most NBIAs, both with regard to putative
brain iron abnormalities as well as with regard to the
severity and progression rate of clinical features. We
therefore believe that, with respect to brain iron loading,
this new model provides insights into early perturbations
in molecular systems during a period corresponding to a
pre-clinical disease stage in which compensatory
responses are still sufﬁcient to maintain the overall
homeostasis of myelin and iron-related systems. For
example, evidence was found for reductions in Lingo1
expression; this might enhance myelination, with anti-
bodies to LINGO1 increasing myelin thickness in early
clinical trials.
27
The high concordance of the expanded gene list
with the 2 human post-mortem NBIA basal ganglia
samples substantiates the clinical relevance of our
observations and testiﬁes to myelin abnormalities in
at least some cases of end-stage NBIA. The direction
of changes often differed between the 2 NBIA samples
but numerous transcripts appeared affected in each,
suggesting that even though the precise nature of the
changes might differ, myelin systems were likely to be
extensively perturbed in both. As reviewed else-
where,28 MBP appears to be the only myelin protein
required for myelin growth; myelin assembly can
occur in the complete absence of other myelin pro-
teins including PLP, MOG, CLDN11 (MIM601326),
MAL and PMP22 (MIM601097). Notably both sam-
ples showed putative increases in MBP transcript lev-
els, suggesting the possibility of ongoing attempts to
enhance myelin production. This could serve to either
increase iron reservoir capacity by increasing myelin
levels above normal or repair myelin damage. While
we have so far found no evidence for clear myelin
damage by light or electron microscopy, the second
possibility is perhaps more likely based on current evi-
dence since, as detailed in our earlier paper, there
appears to be no gross signiﬁcant change in myelin
levels as detected by Luxol fast blue staining.
However the NBIAs exhibit considerable heteroge-
neity. Difﬁculties in obtaining samples due to the
extreme rarity of NBIA cases limits the inferences we
can conﬁdently draw and we have been unable to
attempt validation of the observations statistically or
at the protein level. In addition our samples were
from elderly patients of unknown genetic etiology
who may differ considerably from patients having
more severe NBIAs with childhood onset. For more
complete understanding, including assessment of
whether myelin-related changes are speciﬁcally associ-
ated with one or more NBIA subtypes rather than
non-speciﬁc age-related brain degenerative changes, it
will be important to conduct future analyses using
both arrays and other approaches on greater numbers
of samples, including some more relevant to child-
hood NBIA.
One of the main challenges in these analyses has
been the lack of a comprehensive, evidence-based list
of myelin-related genes, including genes encoding all
the protein components of myelin, genes encoding
enzymes involved in synthesis of myelin lipids and
other myelin components, regulatory genes, for exam-
ple encoding oligodendrocyte and myelin-related
transcription factors, and genes with known links to
myelin diseases. Despite our efforts to address this,
there are other relevant genes not covered by our anal-
yses. For example we have not performed an extensive
search for genes involved in peripheral myelin. It is
also possible that some genes may need to be removed
from the list as new evidence comes to light, although
we have attempted to restrict inclusion to genes for
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which the evidence for relationships with myelin is
relatively strong e.g., myelin abnormalities in patients
with mutations or genetically modiﬁed mouse models.
It will be of interest in the future to investigate
whether any of the 172 myelin-related genes are causal
genes for NBIA using exome sequencing or other
sequencing approaches. The most obvious candidates
to consider ﬁrst would be those with the greatest
expression changes, notably MOBP, MBP and PLP.
Mutations in MOBP and MBP do not appear to have
clear human disease phenotypes but, as reviewed else-
where,29 various MRI studies have reported changes
consistent with brain iron abnormalities in patients
with Pelizaeus-Merzbacher disease, a myelin disease
caused by mutations in PLP. However post-mortem
histopathological studies have yet to be done to con-
ﬁrm these ﬁndings and it is unclear if any such iron
abnormalities are also accompanied by neurodegener-
ation. Findings from Plp deﬁcient mice have shown
neurodegeneration in the form of axonal degeneration
but brain iron levels were not investigated in these
models.30
It is often speculated that excess iron is important
in the pathogenesis of neurodegenerative conditions
such as Alzheimer’s disease but, despite involvement
of NBIA genes, we see little evidence for neurodegen-
erative disease, with neurons spared even in states of
substantial brain iron loading (see Fig. 1). Instead
changes primarily involve myelin. Iron has sometimes
been proposed to be a bystander in NBIA and while
myelin pathology has been reported in a subset of
NBIA patients, it is not usually considered a central
feature of the disease process. Our data provide strong
evidence that disruption of iron-myelin homeostasis is
a prominent and common mechanistic feature under-
lying most, if not all, NBIAs. The results also unex-
pectedly implicate iron in several rare myelin
disorders and also appear likely to provide fresh
insights into several clinically diverse and far more
prevalent conditions including multiple sclerosis,
hemochromatosis and various common psychiatric
disorders.
As noted in our earlier paper,4 interrelationships
between iron and myelin are rarely considered in this
context, although both have been separately proposed
to be contribute to depression, bipolar disorder,
autism, schizophrenia and other psychiatric condi-
tions. As we also detailed previously,4 there have also
been thought-provoking proposals that increased
white matter iron, demyelination and axonal degener-
ation may drive the shift from presymptomatic to clin-
ical Huntington’s disease and development of
psychiatric symptoms.
Venesection or iron chelation is used to treat hemo-
chromatosis and iron chelators are currently being tri-
aled in NBIA patients. These approaches, together
with myelin-based treatments, may provide simple
new strategies for managing these as well as other dis-
orders involving iron and myelin.
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